Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells

Miyake,Naomi; Chikumi,Hiroki; Takata,Miyako; Nakamoto,Masaki; Igishi,Tadashi; Shimizu,Eiji

doi:10.3892/or.2012.1855

Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells

Authors:
- Naomi Miyake
- Hiroki Chikumi
- Miyako Takata
- Masaki Nakamoto
- Tadashi Igishi
- Eiji Shimizu
View Affiliations

Affiliations: Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, Tottori University, 36-1 Nishi-cho, Yonago-shi, Tottori-ken 683-8504, Japan
Published online on: June 12, 2012 https://doi.org/10.3892/or.2012.1855
Pages: 848-854

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mammalian target of rapamycin (mTOR) is a key kinase acting downstream of growth factor receptor PI3K and AKT signaling, leading to processes resulting in increased cell size and proliferation through translation control. Rapamycin, a specific inhibitor of mTOR, results predominately in G1 cell cycle arrest through translation control and occasionally, cell type-dependent apoptosis by an unknown mechanism. In this study, we investigated the effect and mechanism of action of rapamycin on non-small cell lung cancer (NSCLC) cell lines with p53 mutations. Cell proliferation was evaluated by modified MTT assay. The apoptotic effect of rapamycin was measured by caspase-3 activation and flow cytometric analysis of Annexin V binding. The expression of Bcl-2 and the release of cytochrome c from mitochondria were evaluated by western blotting. We found that rapamycin induced apoptosis in NSCLC cell lines with p53 mutations. Western blot analysis demonstrated that rapamycin downregulates the expression levels of Bcl-2, which leads to increased cytochrome c release from mitochondria and subsequent activation of caspase cascades. These findings suggest that rapamycin induces p53-independent apoptosis through downregulation of Bcl-2 and the mitochondrial pathway in NSCLC cell lines as a novel antitumor mechanism.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
2	Delbaldo C, Michiels S, Rolland E, et al: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev. 17:CD0045692007.
3	Hanahan D: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
4	Vignot S, Faivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol. 16:525–537. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shaw RJ and Cantley LC: Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
6	LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
7	Sabers CJ, Martin MM, Brunn GJ, et al: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 270:815–822. 1995. View Article : Google Scholar : PubMed/NCBI
8	Lorenz MC and Heitman J: TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem. 270:27531–27537. 1995. View Article : Google Scholar : PubMed/NCBI
9	Balsara BR, Pei J, Mitsuuchi Y, et al: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 25:2053–2059. 2004. View Article : Google Scholar : PubMed/NCBI
10	Wislez M, Spencer ML, Izzo JG, et al: Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 65:3226–3235. 2005.PubMed/NCBI
11	Marinov M, Fischer B and Arcaro A: Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol. 63:172–182. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gridelli C, Maione P and Rossi A: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 13:139–147. 2008. View Article : Google Scholar : PubMed/NCBI
13	Muthukkumar S, RaMesh TM and Bondada S: Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 60:264–270. 1995. View Article : Google Scholar : PubMed/NCBI
14	Tirado OM, Mateo-Lozano S and Notario V: Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene. 24:3348–3357. 2005. View Article : Google Scholar
15	Zhang JF, Liu JJ, Lu MQ, et al: Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol. 17:162–168. 2007. View Article : Google Scholar : PubMed/NCBI
16	Vega F, Medeiros LJ, Leventaki V, et al: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 66:6589–6597. 2006. View Article : Google Scholar
17	Aguirre D, Boya P, Bellet D, et al: Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis. 9:797–805. 2004. View Article : Google Scholar : PubMed/NCBI
18	Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T and Houghton PJ: p53/p21^CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res. 61:3373–3381. 2001.
19	Huang S, Shu L, Easton J, et al: Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem. 279:36490–36496. 2004. View Article : Google Scholar
20	Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G and Nicolin A: Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer. 37:2121–2128. 2001. View Article : Google Scholar : PubMed/NCBI
21	Boffa DJ, Luan F, Thomas D, et al: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res. 10:293–300. 2004. View Article : Google Scholar : PubMed/NCBI
22	Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 5:2676–2684. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kishimoto M, Kohno T, Okudela K, et al: Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res. 11:512–519. 2005.PubMed/NCBI
24	Okabe T, Okamoto I, Tamura K, et al: Differential constitutive activation of the epidermal growthfactor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 67:2046–2053. 2007. View Article : Google Scholar
25	Mori T, Okamoto H, Takahashi N, Ueda R and Okamoto T: Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett. 465:124–128. 2000. View Article : Google Scholar : PubMed/NCBI
26	Park MJ, Shimizu K, Nakano T, et al: Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma. Cancer Genet Cytogenet. 141:5–13. 2003. View Article : Google Scholar : PubMed/NCBI
27	Nagai Y and Miyazawa H: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
28	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
29	del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 278:687–689. 1997.PubMed/NCBI
30	Gardai SJ, Hildeman DA, Frankel SK, et al: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 279:21085–21095. 2004. View Article : Google Scholar : PubMed/NCBI
31	Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
32	Migita K, Eguchi K, Ichinose Y, et al: Effects of rapamycin on apoptosis of rheumatoid synovial cells. Clin Exp Immunol. 108:199–203. 1997. View Article : Google Scholar : PubMed/NCBI
33	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
34	Zhang YJ, Duan Y and Zheng XF: Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today. 16:325–331. 2011. View Article : Google Scholar : PubMed/NCBI
35	Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI